

Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The ongoing Phase III ASCENT-03 study is evaluating sacituzumab govitecan versus treatment of physician's choice in which of the following settings?**

 - As adjuvant treatment for localized TNBC
 - As first-line treatment for mTNBC**
 - As second-line treatment for mTNBC
 - As late-line treatment for mTNBC
- 2. Which of the following Grade 3 adverse events was most commonly reported in patients receiving sacituzumab for previously treated advanced TNBC in the Phase III ASCENT trial?**

 - Sinus bradycardia
 - Neutropenias**
 - Peripheral neuropathy
 - Nausea
- 3. Recently presented pooled data analysis from pivotal studies of trastuzumab deruxtecan (T-DXd) for patients with HER2-positive metastatic breast cancer (mBC) with brain metastases (BMs) demonstrated which of the following outcomes?**

 - Significant CNS activity with T-DXd for patients with HER2-positive mBC with treated/stable BMs
 - Significant CNS activity with T-DXd for patients with HER2-positive mBC with untreated/active BMs
 - Both a and b**
 - Neither a nor b
- 4. Which of the following receptors is the target of datopotamab deruxtecan (Dato-DXd)?**

 - NRG1
 - MET
 - CEACAM5
 - TROP2**
- 5. Recently presented findings on the combination of Dato-DXd and durvalumab demonstrated robust and durable tumor responses for patients with TNBC in which of the following settings?**

 - As adjuvant therapy for localized TNBC
 - As first-line therapy for unresectable locally advanced/metastatic TNBC**
 - As second-line therapy for unresectable locally advanced/metastatic TNBC
 - As later-line therapy for unresectable locally advanced/metastatic TNBC